What Are Ruxolitinib 5 mg Tablet Jakavi – JAK1/JAK2 Inhibitor?
Ruxolitinib 5 mg tablets, marketed under brand names such as Jakavi and generic alternatives like Rutinib 5 mg, are targeted medications belonging to the Janus kinase (JAK) inhibitor class. They are primarily used in the management of myelofibrosis, polycythemia vera, and other JAK-driven blood disorders.
By selectively blocking JAK1 and JAK2 enzymes, Ruxolitinib helps regulate abnormal blood cell growth and reduces inflammation associated with these conditions.
How Jakavi-Ruxolitinib (Rutinib) 5 mg tablets Works
Ruxolitinib acts on the JAK-STAT signaling pathway, which is often overactive in myeloproliferative diseases. By inhibiting JAK1 and JAK2:
-
It reduces spleen enlargement and associated discomfort
-
Helps lower fatigue and other systemic symptoms
-
Slows or prevents disease progression
This makes Ruxolitinib a highly effective therapy for long-term disease control.
Uses / Indications of Jakavi-Ruxolitinib (Rutinib) 5 mg tablets
Myelofibrosis
-
Reduces spleen size
-
Improves energy levels
-
Helps relieve bone pain, night sweats, and weight loss
Polycythemia Vera
-
Controls elevated red blood cell counts
-
Lowers risk of complications such as blood clots
-
Suitable when patients do not respond adequately to hydroxyurea
Other JAK-Related Disorders
-
May be used under specialist guidance depending on clinical need
Recommended Dose & Administration of Jakavi-Ruxolitinib (Rutinib) 5 mg tablets
-
Dose is determined by the treating physician based on platelet count, symptoms, and response to therapy
-
Tablets should be swallowed whole with water
-
Can be taken with or without food
-
Do not break, crush, or chew the tablets
Patients should follow their prescribed treatment plan closely.
Benefits of Jakavi-Ruxolitinib (Rutinib) 5 mg tablets
-
Targeted action: Directly inhibits JAK1/JAK2 enzymes involved in disease activity
-
Symptom relief: Reduces spleen size, fatigue, and inflammatory symptoms
-
Disease management: Helps maintain stable blood counts and slows disease progression
-
Oral dosing: Convenient once or twice daily tablet form
Side Effects & Precautions of Ruxolitinib 5 mg Tablet Jakavi – JAK1/JAK2 Inhibitor
Common Side Effects
-
Mild dizziness or headache
-
Nausea
-
Upper respiratory infections
Less Common but Serious
-
Reduced platelet or red blood cell counts
-
Increased susceptibility to infections
Important:
-
Regular blood monitoring is essential during treatment
-
Do not adjust your dose without consulting your physician
Storage & Handling
-
Store at room temperature, protected from moisture and light
-
Keep out of reach of children
-
Do not use after the expiration date printed on the packaging
Frequently Asked Questions (FAQs)
Who can take Ruxolitinib 5 mg tablets?
Adults diagnosed with myelofibrosis, polycythemia vera, or related conditions under medical supervision.
Can it be taken with food?
Yes. Ruxolitinib can be taken with or without meals.
Are blood tests required?
Yes. Regular monitoring helps detect changes in blood counts and ensures safe dosing.
Is long-term use safe?
It is commonly used long-term with proper medical guidance and routine follow-up.
Do I need a prescription?
Yes. Ruxolitinib (Jakavi / Rutinib) is a prescription-only medication.